Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$80 Mln
P/E Ratio
--
P/B Ratio
0.66
Industry P/E
--
Debt to Equity
0
ROE
-0.24 %
ROCE
--
Div. Yield
0 %
Book Value
2.68
EPS
-0.71
CFO
$-160.39 Mln
EBITDA
$-184.90 Mln
Net Profit
$-172.04 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ESSA Pharma - ADR
| -1.12 | 13.46 | 0.57 | -71.68 | -33.06 | -15.42 | -35.94 |
|
BSE Sensex*
| 2.15 | 2.99 | 6.05 | 8.41 | 12.05 | 20.28 | 11.39 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
ESSA Pharma - ADR
| 161.90 | -82.25 | 19.03 | 116.91 | 161.90 | -51.93 | -89.99 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.57 | 774.77 | -- | -14.75 | |
| 8.18 | 1,117.76 | 204.5 | 1.52 | |
| 4.04 | 178.71 | -- | -53.27 | |
| 37.62 | 2,923.94 | -- | -27.85 |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
President, CEO & Director
Dr. David Ross Parkinson M.D.
President, CEO & Director
Dr. David Ross Parkinson M.D.
Headquarters
Vancouver, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ESSA Pharma Inc - ADR stood at $ 126 Mln as on 31-Dec-24
The share price of ESSA Pharma Inc - ADR is $1.77 (NASDAQ) as of 25-Apr-2025 16:00 EDT. ESSA Pharma Inc - ADR has given a return of -33.06% in the last 3 years.
ESSA Pharma Inc - ADR has a market capitalisation of $ 80 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of ESSA Pharma Inc - ADR is 0.66 times as on 25-Apr-2025, a 78% discount to its peers’ median range of 2.96 times.
Since, TTM earnings of ESSA Pharma Inc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ESSA Pharma Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of ESSA Pharma Inc - ADR.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
The CEO & director of Dr. David Ross Parkinson M.D.. is ESSA Pharma Inc - ADR, and CFO & Sr. VP is Dr. David Ross Parkinson M.D..
There is no promoter pledging in ESSA Pharma Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
86
|
|
|
23
|
| ESSA Pharma Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-24.74
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of ESSA Pharma Inc - ADR was $0 Mln.
$-0.03
(
